FerGene’s Bladder Cancer Phase III Trial Hits Its Mark

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 6, 2019 at 10:32 AM.

  1. #1 cafead, Dec 6, 2019 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via FerGene, a gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, reported that its Phase III trial of nadofaragene firadenovec (rAd-IFN/Syn3) met its primary endpoint. The trial is evaluating the gene therapy for the treatment of high-grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC).

    article source
     
    Quote

Reply to Thread